Sarepta Therapeutics, Inc. (SRPT) AI Stock Analysis

Sarepta Therapeutics, Inc. is a biopharmaceutical company that develops innovative RNA-targeted therapeutics, gene therapies, and other genetic therapeutic approaches for rare diseases, with a core focus on Duchenne muscular dystrophy. Its commercial treatments include EXONDYS 51 injection and VYONDYS 53 for patients with specific exon-skipping mutations. Sarepta is also advancing clinical pipeline candidates including AMONDYS 45, SRP-5051, and gene therapy candidates such as SRP-9001 for Duchenne micro-dystrophin and SRP-9003 for limb-girdle muscular dystrophies. The company collaborates with strategic partners including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio.

Sarepta grew revenue from $701.9M in FY2021 to $933.0M in FY2022 and $1.24B in FY2023. Revenue accelerated 53.0% to $1.90B in FY2024, when net income reached $235.2M with an operating margin of 11.5%. In FY2025, revenue increased 15.6% to $2.20B while gross margin declined to 59.9%, resulting in an operating margin of -29.9% and a net income of -$713.4M as R&D expense reached $1.52B. Over the trailing twelve months, revenue was $1.97B with an operating margin of 13.0% and a profit margin of -6.9%. In the quarter ended June 30, 2026, quarterly revenue fell 34.3% year-over-year, while quarterly earnings growth was 2663.8%.

As of June 30, 2026, Sarepta held $788.5M in cash and short-term investments against total debt of $1.05B, resulting in net debt of $257.4M. Shareholders' equity was $1.53B on total assets of $3.19B, supported by a current ratio of 4.42 and a debt-to-equity ratio of 0.68. The business has consistently recorded negative cash flows, including an operating cash flow of -$205.5M and free cash flow of -$307.5M in FY2025. In FY2025, capital expenditures were $102.0M, while share buybacks totaled $25.0M.

At a last close of $17.10, Sarepta has a market cap of $1.81B and an enterprise value of $2.26B. The stock trades at a forward P/E of 19.2x, which is above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 0.9x is lower than the peer median of 4.1x, while EV to EBITDA stands at 16.9x versus the peer median of 12.0x. Over the past year, Sarepta returned -26.7%, lagging the S&P 500 (SPY) return of 16.8%, and its 5-year return of -79.7% underperformed SPY's 83.0% gain.

Analyst ratings for Sarepta include 7 Strong Buy, 0 Buy, 12 Hold, 2 Sell, and 3 Strong Sell recommendations. The mean price target is $21.64, representing an implied upside of 26.5% over the last close of $17.10. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.83B and EPS of $4.32, reflecting EPS growth of 185.6%. Sarepta has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Sarepta Therapeutics, Inc. (SRPT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SRPT income statement, SRPT balance sheet, SRPT key metrics, SRPT analyst forecast, SRPT chart. See the SRPT stock overview for the latest quote and news.